MCID: BCT022
MIFTS: 62

Bacterial Infectious Disease

Categories: Infectious diseases

Aliases & Classifications for Bacterial Infectious Disease

MalaCards integrated aliases for Bacterial Infectious Disease:

Name: Bacterial Infectious Disease 12 15
Bacterial Infections 45

Classifications:



External Ids:

Disease Ontology 12 DOID:104
MeSH 45 D001424
NCIt 51 C2890
SNOMED-CT 69 87628006
ICD10 34 A49 A49.9
UMLS 74 C0004623

Summaries for Bacterial Infectious Disease

Disease Ontology : 12 A disease by infectious agent that results in infection, has material basis in Bacteria.

MalaCards based summary : Bacterial Infectious Disease, also known as bacterial infections, is related to commensal bacterial infectious disease and primary bacterial infectious disease. An important gene associated with Bacterial Infectious Disease is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Ertapenem and Meropenem have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and colon, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Bacterial Infectious Disease

Diseases related to Bacterial Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 718)
# Related Disease Score Top Affiliating Genes
1 commensal bacterial infectious disease 34.6 IL10 IL1B IL6 TNF
2 primary bacterial infectious disease 34.1 CRP CXCL8 IFNG IL10 IL17A IL1B
3 myd88 deficiency 33.9 IRAK4 MYD88 TLR2 TLR4
4 irak4 deficiency 32.6 IRAK4 MYD88 TLR2 TLR4
5 osteomyelitis 32.5 CXCL8 IFNG IL10 IL1B IL6 TNF
6 trench fever 32.4 TLR2 TLR4 TNF
7 bacterial pneumonia 32.4 CRP CXCL8 DEFB4A IL17A IL6 TLR4
8 campylobacteriosis 32.4 IFNG IL1B TLR4
9 pyelonephritis 32.4 CRP CXCL8 IL10 IL1B IL6 TLR4
10 bacterial meningitis 32.4 CRP CXCL8 IL10 IL1B IL6 TLR2
11 spotted fever 32.4 IFNG IL10 TNF
12 bacterial sepsis 32.3 CRP CXCL8 IL10 TLR4 TNF
13 shigellosis 32.3 CAMP CXCL8 IL10 IRAK4
14 legionellosis 32.2 IL1B MYD88 TLR2 TLR4 TNF
15 pertussis 32.2 IL10 IL1B IL6 TLR4 TNF
16 leprosy 3 32.2 IFNG IL10 NOD2 TLR2 TNF
17 meningitis 32.2 CRP CXCL8 IFNG IL10 IL1B IL6
18 chorioamnionitis 32.2 CRP CXCL8 IL1B IL6 TLR4 TNF
19 typhoid fever 32.2 CRP IFNG IL1B IL6 TLR4 TNF
20 lyme disease 32.2 CRP IL17A IL1B IL6 TLR2 TNF
21 pyelitis 32.1 CRP CXCL8 IL6 TLR4
22 pyoderma gangrenosum 32.1 CXCL8 NOD2 TNF
23 salmonellosis 32.1 DEFB1 DEFB4A IFNG IL18 IL1B TLR4
24 tonsillitis 32.0 CXCL8 DEFB1 DEFB4A IFNG IL1B IL6
25 leptospirosis 32.0 CRP CXCL8 IFNG IL10 IL1B IL6
26 brucellosis 32.0 CRP CXCL8 IFNG IL10 IL18 IL6
27 q fever 32.0 IFNG IL10 IL1B IL6 NOD2 TLR2
28 guttate psoriasis 32.0 CAMP NOD2
29 melioidosis 31.9 IFNG IL10 IL18 IL6 TLR2 TLR4
30 chlamydia 31.9 CRP CXCL8 IFNG IL10 IL1B IL6
31 mycobacterium tuberculosis 1 31.9 IFNG IL10 IL17A IL18 MYD88 TLR2
32 toxic shock syndrome 31.9 CXCL8 IFNG IL10 IL1B IL6 TLR2
33 bronchitis 31.0 CRP CXCL8 TNF
34 hematopoietic stem cell transplantation 30.9 IFNG IL10 IL6 TNF
35 cystic fibrosis 30.9 CAMP CXCL8 DEFB1 DEFB4A TLR4
36 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.9 IFNG IL10 IL17A
37 autoimmune disease 30.8 IFNG IL10 IL17A IL1B IL6 TNF
38 leishmaniasis 30.8 IFNG IL10 IL1B TLR2 TLR4 TNF
39 dermatitis 30.8 IFNG IL17A IL18 NOD2
40 peritonitis 30.8 CRP CXCL8 IL10 IL1B IL6 TLR2
41 endocarditis 30.8 CRP CXCL8 IL10 IL6 TLR2 TNF
42 human immunodeficiency virus infectious disease 30.7 IFNG IL10 IL6 TNF
43 pulmonary disease, chronic obstructive 30.7 CRP CXCL8 IL17A IL6 TLR2 TNF
44 infective endocarditis 30.7 CRP IL6 TLR2 TNF
45 haemophilus influenzae 30.7 CXCL8 IL1B TLR2 TNF
46 arthritis 30.7 CXCL8 IFNG IL10 IL17A IL18 IL1B
47 acquired immunodeficiency syndrome 30.7 IFNG IL10 IL1B IL6 TNF
48 viral pneumonia 30.6 CRP IL17A IL6
49 mastitis 30.6 CXCL8 IL17A IL6 NOD2 TLR2
50 cutaneous leishmaniasis 30.6 IFNG IL10 TLR2 TLR4 TNF

Graphical network of the top 20 diseases related to Bacterial Infectious Disease:



Diseases related to Bacterial Infectious Disease

Symptoms & Phenotypes for Bacterial Infectious Disease

GenomeRNAi Phenotypes related to Bacterial Infectious Disease according to GeneCards Suite gene sharing:

27 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.88 CXCL8 IL10 IL17A IL18 IL1B MYD88
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.88 CXCL8 IL10 IL17A IL18 IL1B MYD88
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 9.8 NOD2
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.8 CRP
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.8 IL10
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.8 IL10
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.8 CRP
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 9.8 TLR4
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.8 IL10
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.8 IL10
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.8 CRP IL10 NOD2 TLR4
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.8 NOD2
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.8 CRP

MGI Mouse Phenotypes related to Bacterial Infectious Disease:

47 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.36 CAMP CSF3 IFNG IL10 IL17A IL18
2 immune system MP:0005387 10.33 CAMP CRP CSF3 IFNG IL10 IL17A
3 homeostasis/metabolism MP:0005376 10.28 CRP IFNG IL10 IL17A IL18 IL1B
4 cellular MP:0005384 10.24 CAMP IFNG IL10 IL18 IL6 IRAK4
5 cardiovascular system MP:0005385 10.21 CRP IFNG IL10 IL18 IL1B IL6
6 digestive/alimentary MP:0005381 10.18 IFNG IL10 IL17A IL18 IL6 MYD88
7 integument MP:0010771 10.02 CSF3 IFNG IL10 IL18 IL1B IL6
8 neoplasm MP:0002006 9.97 IFNG IL10 IL1B IL6 MYD88 TLR2
9 renal/urinary system MP:0005367 9.8 CSF3 IFNG IL17A IL6 MYD88 TLR2
10 respiratory system MP:0005388 9.76 IFNG IL10 IL17A IL6 MYD88 TLR2
11 skeleton MP:0005390 9.65 IFNG IL10 IL17A IL1B IL6 MYD88
12 vision/eye MP:0005391 9.23 CAMP IFNG IL10 IL18 IL6 MYD88

Drugs & Therapeutics for Bacterial Infectious Disease

Drugs for Bacterial Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 977)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ertapenem Approved, Investigational Phase 4,Phase 3,Phase 2 153832-46-3 150610
2
Meropenem Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 119478-56-7, 96036-03-2 441130 64778
3
Imipenem Approved Phase 4,Phase 3,Phase 2,Phase 1 64221-86-9, 74431-23-5 104838
4
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83905-01-5 447043 55185
5
Cefoxitin Approved Phase 4,Phase 2,Phase 1,Not Applicable 35607-66-0 441199
6
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85721-33-1 2764
7
Cefotaxime Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 63527-52-6 5742673 456256
8
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 26787-78-0 33613
9
Vancomycin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1404-90-6 14969 441141
10
Acetylcysteine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 616-91-1 12035
11
Metronidazole Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 443-48-1 4173
12
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81103-11-9 84029
13
Rabeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 117976-89-3 5029
14
Nitrofurantoin Approved, Vet_approved Phase 4,Not Applicable 67-20-9 5353830
15
Fosfomycin Approved Phase 4,Phase 3,Phase 2,Phase 1 23155-02-4 446987
16
Sulbactam Approved Phase 4,Phase 3,Phase 2 68373-14-8
17
Piperacillin Approved Phase 4,Phase 3,Not Applicable 66258-76-2 43672
18
Polymyxin B Approved, Vet_approved Phase 4,Phase 3,Phase 2 1404-26-8
19
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
20
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
21
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
22
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
23
Rifampicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 13292-46-1 5381226 5458213
24
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 138530-94-6, 103577-45-3 9578005
25
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 103577-45-3 3883
26
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
27
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 73590-58-6 4594
28
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 93-14-1 3516
29
Pantoprazole Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 102625-70-7 4679
30
Cefazolin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 25953-19-9 33255 656510
31
Daptomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 103060-53-3 16129629
32
Teicoplanin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61036-62-2
33
Ofloxacin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 82419-36-1 4583
34
Levofloxacin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 100986-85-4 149096
35
Mupirocin Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 12650-69-0 446596
36
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 18323-44-9 29029
37
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
38
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-63-6 5991
39
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-28-2 5757
40
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28014-46-2
41
Desogestrel Approved Phase 4 54024-22-5 40973
42
Tinidazole Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 19387-91-8 5479
43
Tetracycline Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 60-54-8 5353990
44
Cloxacillin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 61-72-3 6098
45
Pyrazinamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 98-96-4 1046
46
Ethambutol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 74-55-5 14052 3279
47
Isoniazid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 54-85-3 3767
48 Cranberry Approved, Investigational Phase 4,Phase 2,Not Applicable
49
Clotrimazole Approved, Vet_approved Phase 4,Phase 3 23593-75-1 2812
50
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 4844)
# Name Status NCT ID Phase Drugs
1 Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections Unknown status NCT01297842 Phase 4 Ertapenem;Meropenem or Imipenem
2 Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis Unknown status NCT01820026 Phase 4 Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
3 Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy Unknown status NCT01572597 Phase 4 10RAC+acetylcystein;10RAC+metronidazole
4 Study Comparing Nitrofurantoin to Fosfomycin for Acute Urinary Tract Infection in Women Unknown status NCT01966653 Phase 4 nitrofurantoin;fosfomycin
5 Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection Unknown status NCT01760109 Phase 4 Piperacillin Sodium and Sulbactam Sodium
6 Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection Unknown status NCT01897831 Phase 4 xin te mie
7 Efficacy of Polymyxin B Against Infections Caused by Extensively Drug-resistant (XDR) Gram-Negative Bacteria Unknown status NCT02328183 Phase 4 Polymyxin B
8 Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children Unknown status NCT00494624 Phase 4 prednisolone
9 Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin Unknown status NCT02443064 Phase 4 Vancomycin
10 Role of N-Acetylcysteine in Treatment of Bacterial Vaginosis Unknown status NCT01841411 Phase 4 N-Acetyl cysteine;Metronidazole + N-Acetyl cysteine;metronidazole
11 10 vs 14 Days Triple Therapy : H.Pylori Infection Eradication Unknown status NCT03134378 Phase 4 Rabeprazole Sodium 20mg;Clarithromycin 500mg;Amoxicillin 500 Mg
12 Helicobacter Pylori Eradication Study Unknown status NCT03130452 Phase 4 Lansoprazole 30mg;Amoxicillin 1.0g Tab;Clarithromycin 500mg;Metronidazole 500 mg
13 Tailored Therapy for Helicobacter Pylori in Children Unknown status NCT02635191 Phase 4 Tailored Group;Standard group
14 Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole Unknown status NCT02552641 Phase 4 Esomeprazole;Amoxicillin;Clarythromycin
15 Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection Unknown status NCT02249546 Phase 4 N-acetylcysteine + PPI-amoxicillin-clarithromycin;PPI-amoxicillin-clarithromycin
16 Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection Unknown status NCT02237859 Phase 4 Vancomycin
17 Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy Unknown status NCT02108184 Phase 4 Sequential therapy 10 days;Sequential therapy 14 days;Concomitant therapy 10 days;Concomitant therapy 14 days
18 Vascular Surgical Antibiotic Prophylaxis Study (VSAPS 2) Unknown status NCT01612052 Phase 4 Antibiotic Prophylaxis
19 Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections Unknown status NCT01566643 Phase 4 RA5-RACM7;RA3-RACM7;RA7-RACM7
20 14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
21 Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy Unknown status NCT01265069 Phase 4 high dose dual therapy;concomitant therapy
22 A Trial to Evaluate the Loading Dose Required to Achieve Therapeutic Serum Teicoplanin Concentration Timely Unknown status NCT00368498 Phase 4 teicoplanin
23 Community-based Helicobacter Pylori Eradication Unknown status NCT00155389 Phase 4 Helicobacter pylori eradication
24 Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) Unknown status NCT02569632 Phase 4
25 Topical Gentamicin Cream Versus Alternating Gentamicin and Mupirocin Cream in Peritoneal Dialysis Unknown status NCT00751374 Phase 4 gentamicin;gentamicin cream alternating with mupirocin cream
26 The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet Treatment of Bacterial Vaginosis Unknown status NCT03080740 Phase 4 Clindamycin palmitate hydrochloride dispersible tablet;Metronidazole Tablet
27 Probiotic Versus Placebo as Adjuvant for Bacterial Vaginosis Treatment During Pregnancy Unknown status NCT01558388 Phase 4 Lactobacillus acidophilus;Placebo
28 Effect of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring on Vaginal Innate and Inflammatory Biomarkers Unknown status NCT01448291 Phase 4 Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring
29 Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment Unknown status NCT02988089 Phase 4 Clarithromycin susceptibility dependant strategy;2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline );proton pump inhibitor (PPI) and Colloidal Bismuth Pectin;amoxicillin and clarithromycin or amoxicillin and furazolidone;amoxicillin and furazolidone or amoxicillin and tetracycline;amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin
30 Rifampin Combination Therapy Versus Monotherapy in Early Staphylococcal Infections After Total Hip and Knee Arthroplasty Unknown status NCT00423982 Phase 4 Rifampin-combination therapy;Monotherapy
31 Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes Unknown status NCT01782950 Phase 4 Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
32 Probiotics Capsule as Supplemental Therapy for Group B Streptococci Infection and Vaginitis During Pregnancy Unknown status NCT01779193 Phase 4
33 Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia Unknown status NCT00990405 Phase 4 Lansoprzole+Amoxicillin+Clarithromycin
34 NAT2 in Re-challenge of INH in Patients With Hepatitis Unknown status NCT00728546 Phase 4 Isoniazid (Rifinah)
35 Use TST and QFT-RD1 Test to Monitor the Tuberculous Infection in Patients, Close Contact People and Health Care Workers Unknown status NCT00311220 Phase 4 tuberculin for skin test
36 Randomized Controlled Trial of Percutaneous and Intradermal BCG Vaccination. Unknown status NCT00242047 Phase 4
37 Ciprofloxacin for Prevention of BK Infection Unknown status NCT01789203 Phase 4 Ciprofloxacin;placebo
38 Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections Unknown status NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
39 The Efficacy of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease Unknown status NCT01469702 Phase 4 prednison and azithromycin;prednison, azithromycin;prednison, Azenil
40 Influence of BCG on TDaP-IPV Vaccination Unknown status NCT02771782 Phase 4
41 Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand Unknown status NCT02408926 Phase 4
42 Pertussis (Tdap) Vaccination in Pregnancy Unknown status NCT01698346 Phase 4
43 The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients Unknown status NCT00336115 Phase 4
44 Rationale, Design and Methods for the Early Surgery in Infective Endocarditis Study (ENDOVAL) Unknown status NCT00624091 Phase 4
45 Typhoid Fever: Combined vs. Single Antibiotic Therapy Unknown status NCT02224040 Phase 4 ceftriaxone;ceftriaxone and azithromycin;azithromycin;azithromycin and cefixime
46 SDD for Eradicating CRKP Carriage Unknown status NCT01761487 Phase 4
47 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis Unknown status NCT01223976 Phase 4
48 An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster Unknown status NCT00870350 Phase 4
49 The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis Unknown status NCT02588196 Phase 4 Dexamethasone acetate
50 Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4

Search NIH Clinical Center for Bacterial Infectious Disease

Cochrane evidence based reviews: bacterial infections

Genetic Tests for Bacterial Infectious Disease

Anatomical Context for Bacterial Infectious Disease

MalaCards organs/tissues related to Bacterial Infectious Disease:

42
Skin, Testes, Colon, Lung, Liver, Heart, Eye

Publications for Bacterial Infectious Disease

Articles related to Bacterial Infectious Disease:

(show top 50) (show all 2542)
# Title Authors Year
1
Novel PET and Near Infrared Imaging Probes for the Specific Detection of Bacterial Infections Associated With Cardiac Devices. ( 29680350 )
2019
2
Bacterial Infections of the Central Nervous System. ( 29297142 )
2019
3
Selection of antimicrobial frog peptides and temporin-1DRa analogs for treatment of bacterial infections based on their cytotoxicity and differential activity against pathogens. ( 31102497 )
2019
4
Multidrug-Resistant Gram-Negative Bacterial Infections in Solid Organ Transplant Recipients - Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. ( 31102483 )
2019
5
Initial antibiotic treatment of serious bacterial infections. ( 31088097 )
2019
6
Potential of marine natural products against drug-resistant bacterial infections. ( 31031171 )
2019
7
Group B Streptococcus in surgical site and non-invasive bacterial infections worldwide: a systematic review and meta-analysis. ( 31028879 )
2019
8
Development and evaluation of novel topical gel of neem extract for the treatment of bacterial infections. ( 31012982 )
2019
9
Factors associated with serious bacterial infections in infants ≤60 days with hypothermia in the emergency department. ( 31006603 )
2019
10
Bacterial Infections in the Stem Cell Transplant Recipient and Hematologic Malignancy Patient. ( 31005135 )
2019
11
Procalcitonin and Proinflammatory Cytokines in Early Diagnosis of Bacterial Infections after Bronchoscopy. ( 30976333 )
2019
12
Community-based antibiotic delivery for possible serious bacterial infections in neonates in low- and middle-income countries. ( 30970390 )
2019
13
Multifunctional two dimensional Bi2Se3 nanodiscs for combined antibacterial and anti-inflammatory therapy for bacterial infections. ( 30957120 )
2019
14
Monoclonal antibody-based therapies for bacterial infections. ( 30950853 )
2019
15
Saline Environments as a Source of Potential Quorum Sensing Disruptors to Control Bacterial Infections: A Review. ( 30934619 )
2019
16
A Subset of Type I Conventional Dendritic Cells Controls Cutaneous Bacterial Infections through VEGFα-Mediated Recruitment of Neutrophils. ( 30926233 )
2019
17
Antimicrobial-resistant bacterial infections from foods of animal origin: understanding and effectively communicating to consumers. ( 30924543 )
2019
18
S2k guidelines for skin and soft tissue infections Excerpts from the S2k guidelines for "calculated initial parenteral treatment of bacterial infections in adults - update 2018". ( 30920735 )
2019
19
Bacterial Infections Associated with Viperidae Snakebites in Children: A 14-Year Experience at the Hospital Nacional de Niños de Costa Rica†. ( 30915952 )
2019
20
Impact of donor with evidence of bacterial infections on deceased donor liver transplantation: a retrospective observational cohort study in Taiwan. ( 30904845 )
2019
21
How to predict serious bacterial infections in young febrile infants in the emergency department? ( 30904453 )
2019
22
Guanylate-binding proteins at the crossroad of noncanonical inflammasome activation during bacterial infections. ( 30897250 )
2019
23
Cross-Talk Between Antigen Presenting Cells and T Cells Impacts Intestinal Homeostasis, Bacterial Infections, and Tumorigenesis. ( 30894857 )
2019
24
Animal models of orthopaedic infections. A review of rabbit models used to induce long bone bacterial infections. ( 30875284 )
2019
25
Treatment of late bacterial infections resulting from soft-tissue filler injections. ( 30863129 )
2019
26
Efficacy of Aminomethyl Spectinomycins against Complex Upper Respiratory Tract Bacterial Infections. ( 30858215 )
2019
27
First Case of Patient With Two Homozygous Mutations in MYD88 and CARD9 Genes Presenting With Pyogenic Bacterial Infections, Elevated IgE, and Persistent EBV Viremia. ( 30837984 )
2019
28
Acid Sphingomyelinase-Ceramide System in Bacterial Infections. ( 30816675 )
2019
29
Diagnosis of periprosthetic joint bacterial infections by culture of sonication fluid from infected implants. ( 30803320 )
2019
30
Impact of Delayed Therapy in Serious Bacterial Infections: Role of Technology and the Clinician at the Bedside. ( 30797500 )
2019
31
Current Challenges and Perspectives for the Use of Aqueous Plant Extracts in the Management of Bacterial Infections: The Case-Study of Salmonellaenterica Serovars. ( 30795544 )
2019
32
Inducible lung epithelial resistance requires multisource reactive oxygen species generation to protect against bacterial infections. ( 30794556 )
2019
33
A Clinical Prediction Rule to Identify Febrile Infants 60 Days and Younger at Low Risk for Serious Bacterial Infections. ( 30776077 )
2019
34
Optimal antimicrobial duration for common bacterial infections. ( 30765902 )
2019
35
Interest of Eosinophil Count in Bacterial Infections to Predict Antimicrobial Therapy Efficacy. ( 30758492 )
2019
36
Interest of Eosinophil Count in Bacterial Infections to Predict Antimicrobial Therapy Efficacy-Reply. ( 30758488 )
2019
37
Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections. ( 30723876 )
2019
38
The global dissemination of bacterial infections necessitates the study of reverse genomic epidemiology. ( 30715167 )
2019
39
Mixed Viral-Bacterial Infections and Their Effects on Gut Microbiota and Clinical Illnesses in Children. ( 30696865 )
2019
40
Non-critical healthcare tools as a potential source of healthcare-acquired bacterial infections in eastern Ethiopia: A hospital-based cross-sectional study. ( 30693084 )
2019
41
Deciphering the Role of Intramolecular Networking in Cholic Acid-Peptide Conjugates on the Lipopolysaccharide Surface in Combating Gram-Negative Bacterial Infections. ( 30688460 )
2019
42
Limitations of diagnostic tests for bacterial infections. ( 30686500 )
2019
43
Synthetic CpG-ODN rapidly enriches immune compartments in neonatal chicks to induce protective immunity against bacterial infections. ( 30674918 )
2019
44
Impact of Delayed Appropriate Antibiotic Therapy on Patient Outcomes by Antibiotic Resistance Status From Serious Gram-negative Bacterial Infections. ( 30665490 )
2019
45
Bacteria-Responsive Nanoliposomes as Smart Sonotheranostics for Multidrug Resistant Bacterial Infections. ( 30657302 )
2019
46
Presepsin: A promising biomarker for the detection of bacterial infections. ( 30611989 )
2019
47
Synergistic treatment strategies to combat resistant bacterial infections using Schiff base modified nanoparticulate - hydrogel system. ( 30573245 )
2019
48
Smart wound dressing based on κ-carrageenan/locust bean gum/cranberry extract for monitoring bacterial infections. ( 30553333 )
2019
49
Bacteriophages: an overview of the control strategies against multiple bacterial infections in different fields. ( 30485461 )
2019
50
The correlation of crystalline and elemental composition of urinary stones with a history of bacterial infections: TXRF, XRPD and PCR-DGGE studies. ( 30483831 )
2019